Blrx stock website
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary BLRX: Dividend Date & History for Bioline Rx Ltd - ADR